Brain-Computer Interface Company Synchron Secures $200M Funding
Synchron, a New York-based developer of non-surgical brain-computer interface (BCI) technology, has raised $200 million in a Series D funding round. This capital injection aims to speed up commercialization of its first-generation Stentrode BCI platform and support the development of a cutting-edge next-generation interface.
Funding Details and Investors
The new financing brings Synchron’s total funding to $345 million. Double Point Ventures led the round, joined by existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. Additional new investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Technology Overview
The Stentrode platform represents the first endovascular brain-computer interface. Instead of requiring open-brain surgery, it is implanted via a non-surgical catheter procedure. Positioned within the blood vessels, it connects to the motor cortex, capturing and wirelessly transmitting neural signals. This enables users to control digital devices hands-free by translating brain activity into digital commands.
Synchron described Stentrode as "designed to translate brain activity into digital commands without open-brain surgery."
By combining innovative delivery with wireless communication, the Stentrode BCI offers a less invasive option for brain-machine interfacing.
Author’s Summary
Synchron’s $200M funding boost will speed commercialization of its revolutionary Stentrode brain-computer interface and advance development of its next-generation technology.